JP2019534310A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019534310A5 JP2019534310A5 JP2019524868A JP2019524868A JP2019534310A5 JP 2019534310 A5 JP2019534310 A5 JP 2019534310A5 JP 2019524868 A JP2019524868 A JP 2019524868A JP 2019524868 A JP2019524868 A JP 2019524868A JP 2019534310 A5 JP2019534310 A5 JP 2019534310A5
- Authority
- JP
- Japan
- Prior art keywords
- group
- substituted
- groups
- alkyl
- independently selected
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 125000005843 halogen group Chemical group 0.000 claims description 118
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims description 114
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 claims description 103
- 125000001424 substituent group Chemical group 0.000 claims description 97
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 76
- 125000000623 heterocyclic group Chemical group 0.000 claims description 64
- 150000001875 compounds Chemical class 0.000 claims description 47
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims description 46
- 125000003277 amino group Chemical group 0.000 claims description 46
- 125000003118 aryl group Chemical group 0.000 claims description 44
- 125000003367 polycyclic group Chemical group 0.000 claims description 44
- 125000001072 heteroaryl group Chemical group 0.000 claims description 43
- 125000002950 monocyclic group Chemical group 0.000 claims description 43
- 125000004432 carbon atom Chemical group C* 0.000 claims description 42
- 150000003839 salts Chemical class 0.000 claims description 36
- 125000000217 alkyl group Chemical group 0.000 claims description 30
- 229910052799 carbon Inorganic materials 0.000 claims description 30
- 229910052757 nitrogen Inorganic materials 0.000 claims description 28
- 125000004433 nitrogen atom Chemical group N* 0.000 claims description 24
- 125000004122 cyclic group Chemical group 0.000 claims description 22
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 19
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 17
- 230000036542 oxidative stress Effects 0.000 claims description 14
- 230000004065 mitochondrial dysfunction Effects 0.000 claims description 13
- 150000002825 nitriles Chemical group 0.000 claims description 13
- 125000000000 cycloalkoxy group Chemical group 0.000 claims description 12
- 125000000008 (C1-C10) alkyl group Chemical group 0.000 claims description 9
- 201000010099 disease Diseases 0.000 claims description 9
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 9
- 239000008194 pharmaceutical composition Substances 0.000 claims description 9
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 8
- 238000006467 substitution reaction Methods 0.000 claims description 8
- 125000002723 alicyclic group Chemical group 0.000 claims description 7
- 125000004750 (C1-C6) alkylaminosulfonyl group Chemical group 0.000 claims description 6
- 125000004916 (C1-C6) alkylcarbonyl group Chemical group 0.000 claims description 6
- 125000004739 (C1-C6) alkylsulfonyl group Chemical group 0.000 claims description 6
- 125000003545 alkoxy group Chemical group 0.000 claims description 6
- JFDZBHWFFUWGJE-UHFFFAOYSA-N benzonitrile Chemical compound N#CC1=CC=CC=C1 JFDZBHWFFUWGJE-UHFFFAOYSA-N 0.000 claims description 6
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 claims description 5
- 125000001153 fluoro group Chemical group F* 0.000 claims description 5
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 claims description 4
- 125000002140 imidazol-4-yl group Chemical group [H]N1C([H])=NC([*])=C1[H] 0.000 claims description 4
- 230000002265 prevention Effects 0.000 claims description 4
- 239000003795 chemical substances by application Substances 0.000 claims description 3
- 230000001225 therapeutic effect Effects 0.000 claims description 3
- KZRTZNQJKJVRKK-UHFFFAOYSA-N 2-(diethylamino)-4-(2-methylphenyl)benzo[e]benzimidazol-5-one Chemical compound CCN(CC)C1=NC2=C(C(=O)C3=CC=CC=C3C2=N1)C1=C(C)C=CC=C1 KZRTZNQJKJVRKK-UHFFFAOYSA-N 0.000 claims description 2
- FUSHVQMWLCUJHF-UHFFFAOYSA-N 2-(dimethylamino)-4-(2-methylphenyl)benzo[e]benzimidazol-5-one Chemical compound CN(C)C1=NC2=C(C(=O)C3=CC=CC=C3C2=N1)C1=C(C)C=CC=C1 FUSHVQMWLCUJHF-UHFFFAOYSA-N 0.000 claims description 2
- LJIMSMKQCLDQDA-UHFFFAOYSA-N 2-(dimethylamino)-4-(2-morpholin-4-ylphenyl)benzo[e]benzimidazol-5-one Chemical compound CN(C)C1=NC2=C(C(=O)C3=CC=CC=C3C2=N1)C1=C(C=CC=C1)N1CCOCC1 LJIMSMKQCLDQDA-UHFFFAOYSA-N 0.000 claims description 2
- RQTPHAKBTKBPDS-UHFFFAOYSA-N 2-(dimethylamino)-4-(4-methylphenyl)benzo[e]benzimidazol-5-one Chemical compound CN(C)C1=NC2=C(C3=CC=C(C)C=C3)C(=O)C3=CC=CC=C3C2=N1 RQTPHAKBTKBPDS-UHFFFAOYSA-N 0.000 claims description 2
- NLIMKLXBRWLMMH-UHFFFAOYSA-N 2-(dimethylamino)-4-[2-(trifluoromethyl)phenyl]benzo[e]benzimidazol-5-one Chemical compound CN(C)C1=NC2=C(C(=O)C3=CC=CC=C3C2=N1)C1=C(C=CC=C1)C(F)(F)F NLIMKLXBRWLMMH-UHFFFAOYSA-N 0.000 claims description 2
- UIFAQSYTRGUNKX-UHFFFAOYSA-N 2-(dimethylamino)-4-[2-methyl-4-(trifluoromethoxy)phenyl]benzo[e]benzimidazol-5-one Chemical compound CN(C)C1=NC2=C(C(=O)C3=CC=CC=C3C2=N1)C1=C(C)C=C(OC(F)(F)F)C=C1 UIFAQSYTRGUNKX-UHFFFAOYSA-N 0.000 claims description 2
- RQONURUBMIPAOP-UHFFFAOYSA-N 2-(dimethylamino)-4-[2-methyl-4-(trifluoromethyl)phenyl]benzo[e]benzimidazol-5-one Chemical compound CN(C)C1=NC2=C(C(=O)C3=CC=CC=C3C2=N1)C1=C(C)C=C(C=C1)C(F)(F)F RQONURUBMIPAOP-UHFFFAOYSA-N 0.000 claims description 2
- GXGLFFFMHFQHSC-UHFFFAOYSA-N 4-(2-chlorophenyl)-2-(dimethylamino)benzo[e]benzimidazol-5-one Chemical compound CN(C)C1=NC2=C(C(=O)C3=CC=CC=C3C2=N1)C1=C(Cl)C=CC=C1 GXGLFFFMHFQHSC-UHFFFAOYSA-N 0.000 claims description 2
- AXTVRMARIOTHDJ-UHFFFAOYSA-N 4-(2-methylphenyl)-2-(4-methylpiperazin-1-yl)benzo[e]benzimidazol-5-one Chemical compound CN1CCN(CC1)C1=NC2=C(C(=O)C3=CC=CC=C3C2=N1)C1=C(C)C=CC=C1 AXTVRMARIOTHDJ-UHFFFAOYSA-N 0.000 claims description 2
- BEPDXECDKPQHCH-UHFFFAOYSA-N N=1N(C(=C(C2=C3C(=NC(=N3)N(C)C)C3=C(C2=O)C=CC=C3)C=1C)C)C Chemical compound N=1N(C(=C(C2=C3C(=NC(=N3)N(C)C)C3=C(C2=O)C=CC=C3)C=1C)C)C BEPDXECDKPQHCH-UHFFFAOYSA-N 0.000 claims description 2
- YZCKVEUIGOORGS-IGMARMGPSA-N Protium Chemical compound [1H] YZCKVEUIGOORGS-IGMARMGPSA-N 0.000 claims description 2
- 239000004480 active ingredient Substances 0.000 claims description 2
- 239000003814 drug Substances 0.000 claims description 2
- 238000004519 manufacturing process Methods 0.000 claims description 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims 1
- -1 Chloro-4-methoxyphenyl Chemical group 0.000 claims 1
- 239000003638 chemical reducing agent Substances 0.000 claims 1
- 125000002147 dimethylamino group Chemical group [H]C([H])([H])N(*)C([H])([H])[H] 0.000 claims 1
- JLXZMLLNPNOODV-UHFFFAOYSA-N imidazol-4-one Chemical compound O=C1C=NC=N1 JLXZMLLNPNOODV-UHFFFAOYSA-N 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- BENGSVASFLEXGZ-UHFFFAOYSA-N 4-(2-chloro-4-methoxyphenyl)-2-(dimethylamino)benzo[e]benzimidazol-5-one Chemical compound COC1=CC(Cl)=C(C=C1)C1=C2N=C(N=C2C2=CC=CC=C2C1=O)N(C)C BENGSVASFLEXGZ-UHFFFAOYSA-N 0.000 description 2
- 125000002837 carbocyclic group Chemical group 0.000 description 2
- 230000004064 dysfunction Effects 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 230000000069 prophylactic effect Effects 0.000 description 2
- 208000011580 syndromic disease Diseases 0.000 description 2
- 0 *C1=C2N=C(N(*)*)N=C2c2ccccc2C1=O Chemical compound *C1=C2N=C(N(*)*)N=C2c2ccccc2C1=O 0.000 description 1
- 208000010444 Acidosis Diseases 0.000 description 1
- 208000024827 Alzheimer disease Diseases 0.000 description 1
- 201000001320 Atherosclerosis Diseases 0.000 description 1
- 208000014644 Brain disease Diseases 0.000 description 1
- QGCKIQHFSRPRRO-UHFFFAOYSA-N CN(C)C(N=C1c2c3cccc2)=NC1=C(c1cccc(OC)c1Cl)C3=O Chemical compound CN(C)C(N=C1c2c3cccc2)=NC1=C(c1cccc(OC)c1Cl)C3=O QGCKIQHFSRPRRO-UHFFFAOYSA-N 0.000 description 1
- RUINRYPKPLLIFA-UHFFFAOYSA-N Cc(cc(cc1)OC)c1C1=C2N=C(N(C)C)N=C2c(cccc2)c2C1=O Chemical compound Cc(cc(cc1)OC)c1C1=C2N=C(N(C)C)N=C2c(cccc2)c2C1=O RUINRYPKPLLIFA-UHFFFAOYSA-N 0.000 description 1
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 description 1
- 208000032274 Encephalopathy Diseases 0.000 description 1
- 208000023105 Huntington disease Diseases 0.000 description 1
- 208000035177 MELAS Diseases 0.000 description 1
- 208000002569 Machado-Joseph Disease Diseases 0.000 description 1
- 206010058799 Mitochondrial encephalomyopathy Diseases 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 208000012902 Nervous system disease Diseases 0.000 description 1
- 208000018737 Parkinson disease Diseases 0.000 description 1
- 208000006011 Stroke Diseases 0.000 description 1
- 230000007950 acidosis Effects 0.000 description 1
- 208000026545 acidosis disease Diseases 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 230000001476 alcoholic effect Effects 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 206010008118 cerebral infarction Diseases 0.000 description 1
- 208000026106 cerebrovascular disease Diseases 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 208000014188 hereditary optic neuropathy Diseases 0.000 description 1
- 208000037805 labour Diseases 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 201000010901 lateral sclerosis Diseases 0.000 description 1
- 208000019423 liver disease Diseases 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 210000003470 mitochondria Anatomy 0.000 description 1
- 208000005264 motor neuron disease Diseases 0.000 description 1
- 230000003387 muscular Effects 0.000 description 1
- 208000010125 myocardial infarction Diseases 0.000 description 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2022089435A JP2022107730A (ja) | 2016-11-15 | 2022-06-01 | ２－置換アミノ－ナフト［１，２－ｄ］イミダゾール－５－オン化合物またはその製薬学上許容される塩 |
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2016222028 | 2016-11-15 | ||
| JP2016222028 | 2016-11-15 | ||
| JP2016250981A JP2018083799A (ja) | 2016-11-15 | 2016-12-26 | ２−置換アミノ−ナフト［１，２−ｄ］イミダゾール−５−オン化合物またはその製薬学上許容される塩 |
| JP2016250981 | 2016-12-26 | ||
| PCT/US2017/061879 WO2018093957A1 (en) | 2016-11-15 | 2017-11-15 | 2-substituted amino-naphth[1,2-d]imidazol-5-one compounds or pharmaceutically acceptable salts thereof cross reference to related applications |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022089435A Division JP2022107730A (ja) | 2016-11-15 | 2022-06-01 | ２－置換アミノ－ナフト［１，２－ｄ］イミダゾール－５－オン化合物またはその製薬学上許容される塩 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2019534310A JP2019534310A (ja) | 2019-11-28 |
| JP2019534310A5 true JP2019534310A5 (enExample) | 2021-01-21 |
| JP7083826B2 JP7083826B2 (ja) | 2022-06-13 |
Family
ID=62237007
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016250981A Pending JP2018083799A (ja) | 2016-11-15 | 2016-12-26 | ２−置換アミノ−ナフト［１，２−ｄ］イミダゾール−５−オン化合物またはその製薬学上許容される塩 |
| JP2019524868A Active JP7083826B2 (ja) | 2016-11-15 | 2017-11-15 | ２－置換アミノ－ナフト［１，２－ｄ］イミダゾール－５－オン化合物またはその製薬学上許容される塩 |
| JP2022089435A Withdrawn JP2022107730A (ja) | 2016-11-15 | 2022-06-01 | ２－置換アミノ－ナフト［１，２－ｄ］イミダゾール－５－オン化合物またはその製薬学上許容される塩 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016250981A Pending JP2018083799A (ja) | 2016-11-15 | 2016-12-26 | ２−置換アミノ−ナフト［１，２−ｄ］イミダゾール−５−オン化合物またはその製薬学上許容される塩 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022089435A Withdrawn JP2022107730A (ja) | 2016-11-15 | 2022-06-01 | ２－置換アミノ－ナフト［１，２－ｄ］イミダゾール－５－オン化合物またはその製薬学上許容される塩 |
Country Status (9)
| Country | Link |
|---|---|
| US (3) | US10738014B2 (enExample) |
| EP (2) | EP3541814B1 (enExample) |
| JP (3) | JP2018083799A (enExample) |
| CN (1) | CN110023311B (enExample) |
| CA (1) | CA3082764A1 (enExample) |
| ES (1) | ES2898836T3 (enExample) |
| HU (1) | HUE056922T2 (enExample) |
| PL (1) | PL3541814T3 (enExample) |
| PT (1) | PT3541814T (enExample) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3456707B1 (en) | 2007-11-06 | 2020-04-15 | PTC Therapeutics, Inc. | 4- (p-quinonyl)-2-hydroxybutanamide derivatives for treatment of mitochondrial diseases |
| BR112017012988B1 (pt) | 2014-12-16 | 2023-10-03 | Ptc Therapeutics, Inc | Formas polimoráficas e amorfas de (r)-2-hidroxi-2- metil-4- (2,4,5-trimetil-3,6-dioxociclohexa-1,4-dienil) butanamida |
| JP2018083799A (ja) | 2016-11-15 | 2018-05-31 | バイオエレクトロン テクノロジー コーポレイション | ２−置換アミノ−ナフト［１，２−ｄ］イミダゾール−５−オン化合物またはその製薬学上許容される塩 |
| BR112021002165A2 (pt) | 2018-08-06 | 2021-05-04 | The Board Of Trustees Of The Leland Stanford Junior University | composto, composição farmacêutica, e, métodos para tratar uma doença neurodegenerativa e deficiência cognitiva associada ao envelhecimento e neuroinflamação |
| MX2021004329A (es) | 2018-10-17 | 2021-06-08 | Ptc Therapeutics Inc | 2,3,5-trimetil-6-nonilciclohexa-2,5-dien-1,4-diona para suprimir y tratar alfa-sinucleinopatias, tauopatias y otros trastornos. |
| CN116997548A (zh) | 2020-05-13 | 2023-11-03 | Chdi基金会股份有限公司 | 用于治疗亨廷顿病的htt调节剂 |
| EP4163277B1 (en) | 2021-02-25 | 2026-01-14 | Aptabio Therapeutics Inc. | Novel pyrazole derivatives |
| MX2024000445A (es) | 2021-07-08 | 2024-04-05 | Ptc Therapeutics Inc | Composiciones farmaceuticas que comprenden 2,3,5-trimetil-6-nonilc iclohexa-2,5-dieno-1,4-diona. |
| US12281116B2 (en) | 2021-11-17 | 2025-04-22 | Chdi Foundation, Inc. | HTT modulators for treating Huntington's disease |
Family Cites Families (65)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB8605032D0 (en) * | 1986-02-28 | 1986-04-09 | Shell Int Research | Fungicides |
| JPH01193253A (ja) * | 1988-01-29 | 1989-08-03 | Taisho Pharmaceut Co Ltd | 置換イミダゾール化合物 |
| US6232060B1 (en) | 1996-01-19 | 2001-05-15 | Galileo Laboratories, Inc. | Assay system for anti-stress agents |
| US5801159A (en) | 1996-02-23 | 1998-09-01 | Galileo Laboratories, Inc. | Method and composition for inhibiting cellular irreversible changes due to stress |
| US7034054B2 (en) | 2000-12-15 | 2006-04-25 | Galileo Pharmaceuticals, Inc. | Methods for the prevention and treatment of cerebral ischemia using non-alpha tocopherols |
| US6608196B2 (en) | 2001-05-03 | 2003-08-19 | Galileo Pharmaceuticals, Inc. | Process for solid supported synthesis of pyruvate-derived compounds |
| US6667330B2 (en) | 2002-01-31 | 2003-12-23 | Galileo Pharmaceuticals, Inc. | Furanone derivatives |
| US6653346B1 (en) | 2002-02-07 | 2003-11-25 | Galileo Pharmaceuticals, Inc. | Cytoprotective benzofuran derivatives |
| WO2004042353A2 (en) | 2002-10-30 | 2004-05-21 | Galileo Pharmaceuticals, Inc. | Identifying therapeutic compounds based on their physical-chemical properties |
| US20050065099A1 (en) | 2003-09-19 | 2005-03-24 | Gail Walkinshaw | Treatment of mitochondrial diseases |
| US7393662B2 (en) | 2004-09-03 | 2008-07-01 | Centocor, Inc. | Human EPO mimetic hinge core mimetibodies, compositions, methods and uses |
| PT2471530T (pt) | 2005-06-01 | 2017-04-19 | Edison Pharmaceuticals Inc | Produtos terapêuticos com atividade redox para o tratamento de doenças mitocondriais e de outras condições e modulação de biomarcadores energéticos |
| JP2009508867A (ja) | 2005-09-15 | 2009-03-05 | エジソン ファーマシューティカルズ， インコーポレイテッド | ミトコンドリア病および関連した様態の治療ならびにエネルギーバイオマーカーの調節のための酸化還元活性治療剤のテイル改変体 |
| EP1986636B1 (en) | 2006-02-22 | 2013-04-24 | Edison Pharmaceuticals, Inc. | Phenol and 1,4-benzoquinone derivatives for use in the treatment of mitochondrial diseases |
| AU2008205263A1 (en) | 2007-01-10 | 2008-07-17 | Edison Pharmaceuticals, Inc. | Treatment of respiratory chain disorders using compounds having erythropoietin or thrombopoietin activity |
| EP3456707B1 (en) | 2007-11-06 | 2020-04-15 | PTC Therapeutics, Inc. | 4- (p-quinonyl)-2-hydroxybutanamide derivatives for treatment of mitochondrial diseases |
| CA2710253A1 (en) | 2008-01-07 | 2009-07-16 | Centocor Ortho Biotech Inc. | Method of treating erythropoietin hyporesponsive anemias |
| JP5649454B2 (ja) | 2008-01-08 | 2015-01-07 | エジソン ファーマシューティカルズ， インコーポレイテッド | ミトコンドリア病の処置のための（ヘテロ）アリール−ｐ−キノン誘導体 |
| EP2262508B1 (en) | 2008-03-05 | 2018-10-03 | BioElectron Technology Corporation | SUBSTITUTED-p-QUINONE DERIVATIVES FOR TREATMENT OF OXIDATIVE STRESS DISEASES |
| CA2717741C (en) | 2008-03-05 | 2018-04-03 | Ptc Therapeutics, Inc. | Treatment of hearing and balance impairments with redox-active therapeutics |
| EP2303309A2 (en) | 2008-05-22 | 2011-04-06 | Edison Pharmaceuticals, Inc. | Treatment of mitochondrial diseases with an erythropoietin mimetic |
| EP2303824B1 (en) | 2008-06-25 | 2015-03-25 | Edison Pharmaceuticals, Inc. | 2-heterocyclylaminoalkyl-(p-quinone) derivatives for treatment of oxidative stress diseases |
| US20100010100A1 (en) | 2008-07-09 | 2010-01-14 | Hinman Andrew W | Dermatological compositions with anti-aging and skin even-toning properties |
| WO2010014758A1 (en) | 2008-07-30 | 2010-02-04 | Edison Pharmaceuticals, Inc. | Use of hydrogenated pyrido[4,3-b] indoles for the treatment of oxidative stress |
| WO2010014361A1 (en) | 2008-07-30 | 2010-02-04 | Edison Pharmaceuticals, Inc. | Naphthoquinone compositions with anti-aging, anti- inflammatory and skin even-toning properties |
| US8314153B2 (en) | 2008-09-10 | 2012-11-20 | Edison Pharmaceuticals, Inc. | Treatment of pervasive developmental disorders with redox-active therapeutics |
| EP2362726B1 (en) | 2008-10-14 | 2018-08-08 | Bioelectron Technology Corporation | Treatment of oxidative stress disorders including contrast nephropathy, radiation damage and disruptions in the function of red cells |
| PT2963006T (pt) | 2008-10-28 | 2018-12-14 | Bioelectron Tech Corp | Composição contendo alfa-tocotrienol quinona e seus intermediários |
| US20120136048A1 (en) | 2009-04-28 | 2012-05-31 | Miller Guy M | Topical, periocular, or intraocular use of tocotrienols for the treatment of ophthalmic diseases |
| WO2010126909A1 (en) | 2009-04-28 | 2010-11-04 | Edison Pharmaceuticals, Inc. | Formulation of tocotrienol quinones for the treatment of ophthalmic diseases |
| MX2011013558A (es) | 2009-06-25 | 2012-04-30 | Ampere Life Sciences Inc | Tratamiento del trastorno pervasivo del desarrollo con tocotrienoles o extractos de tocotrienoles enriquecidos. |
| SI2470168T1 (en) | 2009-08-26 | 2018-05-31 | Bioelectron Technology Corporation | Procedures for the prevention and treatment of brain ischemia |
| EP2519232A1 (en) | 2009-12-31 | 2012-11-07 | Edison Pharmaceuticals, Inc. | Treatment of leigh syndrome and leigh-like syndrome with tocotrienol quinones |
| EP2545025A1 (en) | 2010-03-09 | 2013-01-16 | Edison Pharmaceuticals, Inc. | Synthesis of alpha-tocopherolquinone derivatives, and methods of using the same |
| WO2011113018A1 (en) | 2010-03-12 | 2011-09-15 | Ampere Life Sciences, Inc. | Measurement and control of biological time |
| US20130116336A1 (en) | 2010-04-06 | 2013-05-09 | William D. Shrader | Treatment of ataxia telangiectasia |
| CA2797581A1 (en) | 2010-04-27 | 2011-11-03 | Edison Pharmaceuticals, Inc. | Formulations of quinones for the treatment of ophthalmic diseases |
| WO2012009271A1 (en) | 2010-07-14 | 2012-01-19 | Penwest Pharmaceuticals Co. | Methods of providing anticoagulation effects in subjects |
| SG187744A1 (en) | 2010-08-06 | 2013-03-28 | Edison Pharmaceuticals Inc | Treatment of mitochondrial diseases with naphthoquinones |
| US20120295985A1 (en) | 2010-11-19 | 2012-11-22 | Miller Guy M | Methods for improving blood glucose control |
| WO2012154613A1 (en) | 2011-05-06 | 2012-11-15 | Edison Pharmaceuticals, Inc. | Improved process for the preparation of d-alpha-tocotrienol from natural extracts |
| WO2012170773A1 (en) | 2011-06-08 | 2012-12-13 | Edison Pharmaceuticals, Inc. | Adjunctive therapy for the treatment of mitochondrial disorders with quinones and naphthoquinones |
| WO2012174286A1 (en) | 2011-06-14 | 2012-12-20 | Edison Pharmaceuticals, Inc. | Catechol derivatives for treatment of oxidative stress diseases |
| WO2013006736A1 (en) | 2011-07-06 | 2013-01-10 | Edison Pharmaceuticals, Inc | Treatment of leigh syndrome and leigh-like syndrome, including complications of sucla2 mutations, with tocotrienol quinones |
| ES2795798T3 (es) | 2011-07-06 | 2020-11-24 | Ptc Therapeutics Inc | Tratamiento de aciduria metilmalónica, aciduria isovalérica, y otras acidurias orgánicas con tocotrienol quinonas |
| WO2013013078A1 (en) | 2011-07-19 | 2013-01-24 | Edison Pharmeceuticals, Inc. | Methods for selective oxidation of alpha tocotrienol in the presence of non-alpha tocotrienols |
| US9629815B2 (en) | 2012-09-07 | 2017-04-25 | Bioelectron Technology Corporation | Benzoquinone derivatives for treating oxidative stress disorders |
| EA031098B1 (ru) | 2013-03-08 | 2018-11-30 | Юнилевер Н.В. | Соединения резорцина для дерматологического применения |
| US20140275045A1 (en) | 2013-03-15 | 2014-09-18 | Edison Pharmaceuticals, Inc. | Phenazine-3-one and phenothiazine-3-one derivatives for treatment of oxidative stress disorders |
| US10189830B2 (en) | 2013-03-15 | 2019-01-29 | Bioelectron Technology Corporation | Alkyl-heteroaryl substituted quinone derivatives for treatment of oxidative stress disorders |
| US9296712B2 (en) | 2013-03-15 | 2016-03-29 | Edison Pharmaceuticals, Inc. | Resorufin derivatives for treatment of oxidative stress disorders |
| AU2014273891A1 (en) * | 2013-05-31 | 2015-12-24 | Bioelectron Technology Corporation | Carboxylic acid derivatives for treatment of oxidative stress disorders |
| MX377202B (es) * | 2013-12-30 | 2025-03-07 | Yungjin Pharmaceutical Co Ltd | Derivado basado en 1,2-naftoquinona y metodo de preparacion del mismo. |
| JP6695275B2 (ja) * | 2014-02-07 | 2020-05-20 | ボストン バイオメディカル， インコーポレイテッド | ３−置換カルボニル−ナフト［２，３−ｂ］フラン誘導体又はその薬学的に許容される塩 |
| BR112017012988B1 (pt) | 2014-12-16 | 2023-10-03 | Ptc Therapeutics, Inc | Formas polimoráficas e amorfas de (r)-2-hidroxi-2- metil-4- (2,4,5-trimetil-3,6-dioxociclohexa-1,4-dienil) butanamida |
| US20180002247A1 (en) | 2014-12-16 | 2018-01-04 | Bioelectron Technology Corporation | Methods for chiral resolution of trolox |
| JP2018502127A (ja) | 2015-01-12 | 2018-01-25 | バイオエレクトロン テクノロジー コーポレイション | 放射線被曝に対する防護のためのキノン |
| WO2017106786A1 (en) | 2015-12-16 | 2017-06-22 | Bioelectron Technology Corporation | Improved methods for enriching alpha-tocotrienol from mixed tocol compositions |
| WO2017106803A1 (en) | 2015-12-17 | 2017-06-22 | Bioelectron Technology Corporation | Flouroalkyl, flouroalkoxy, phenoxy, heteroaryloxy, alkoxy, and amine 1,4-benzoquinone derivatives for treatment of oxidative stress disorders |
| WO2017123823A1 (en) | 2016-01-12 | 2017-07-20 | Bioelectron Technology Corporation | Alkyl-, acyl-, urea-, and aza-uracil sulfide:quinone oxidoreductase inhibitors |
| WO2017123822A1 (en) | 2016-01-12 | 2017-07-20 | Bioelectron Technology Corporation | Tocopherol and tocotrienol quinone derivatives for increasing thiosulfate levels or decreasing hydrogen sulfide levels |
| US20190241497A1 (en) | 2016-10-28 | 2019-08-08 | Andrew W. Hinman | Methods for analyzing p-hydroquinone levels and ratios |
| JP2018083799A (ja) | 2016-11-15 | 2018-05-31 | バイオエレクトロン テクノロジー コーポレイション | ２−置換アミノ−ナフト［１，２−ｄ］イミダゾール−５−オン化合物またはその製薬学上許容される塩 |
| WO2018129411A1 (en) | 2017-01-06 | 2018-07-12 | Bioelectron Technology Corporation | Aryl- and heteroaryl-resorufin derivatives for treatment of oxidative stress disorders and liver and kidney disorders |
| US20180333389A1 (en) | 2017-04-14 | 2018-11-22 | Bioelectron Technology Corporation | Vitamin e compositions and methods of use therefor |
-
2016
- 2016-12-26 JP JP2016250981A patent/JP2018083799A/ja active Pending
-
2017
- 2017-11-15 EP EP17817338.1A patent/EP3541814B1/en active Active
- 2017-11-15 PT PT178173381T patent/PT3541814T/pt unknown
- 2017-11-15 EP EP21202648.8A patent/EP3971182A1/en active Pending
- 2017-11-15 HU HUE17817338A patent/HUE056922T2/hu unknown
- 2017-11-15 ES ES17817338T patent/ES2898836T3/es active Active
- 2017-11-15 JP JP2019524868A patent/JP7083826B2/ja active Active
- 2017-11-15 CA CA3082764A patent/CA3082764A1/en active Pending
- 2017-11-15 CN CN201780070427.0A patent/CN110023311B/zh active Active
- 2017-11-15 PL PL17817338T patent/PL3541814T3/pl unknown
- 2017-11-15 US US16/349,940 patent/US10738014B2/en active Active
-
2020
- 2020-08-10 US US16/989,582 patent/US11390588B2/en active Active
-
2022
- 2022-06-01 JP JP2022089435A patent/JP2022107730A/ja not_active Withdrawn
- 2022-07-11 US US17/862,290 patent/US12281083B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2019534310A5 (enExample) | ||
| JP2014502641A5 (enExample) | ||
| HRP20180199T1 (hr) | Urea derivati ili njihove farmakološki prihvatljive soli korisni kao agonisti formil peptidnom receptoru-sličnom i (fprl-1) | |
| JP2014517050A5 (enExample) | ||
| JP2017529382A5 (enExample) | ||
| CN114072396A (zh) | 作为dna-pk抑制剂的喹啉和噌啉衍生物 | |
| RU2011108026A (ru) | Комбинированная терапия туберкулеза | |
| RU2018120330A (ru) | Химерные соединения, осуществляющие нацеливание для протеолиза, и способы их получения и применения | |
| RU2017145930A (ru) | МОДУЛЯТОРЫ ROR ГАММА (RORγ) | |
| JP2018502925A5 (enExample) | ||
| JP2017505293A5 (enExample) | ||
| KR20150046110A (ko) | 피르페니돈 치료제의 투여 방법 | |
| JP2017511339A5 (enExample) | ||
| JP2016505637A5 (enExample) | ||
| RU2014135436A (ru) | Комбинация ингибитора rtk с антиэстрогеном и ее применение для лечения рака | |
| JP2014532730A5 (ja) | オピオイド受容体の調節物質およびそれを含む薬学的組成物 | |
| JP2017506257A5 (enExample) | ||
| JP2014513123A5 (enExample) | ||
| JP2013518914A5 (enExample) | ||
| RU2016132858A (ru) | Производные фторнафтила | |
| Fischer et al. | Results of the safety run-in phase of CLL14 (BO25323): a prospective, open-label, multicenter randomized phase III trial to compare the efficacy and safety of obinutuzumab and venetoclax (GDC-0199/ABT-199) with obinutuzumab and chlorambucil in patients with previously untreated CLL and coexisting medical conditions | |
| JP2021500334A5 (enExample) | ||
| JP2009541387A5 (enExample) | ||
| JP2012526772A5 (enExample) | ||
| AU2008222890B2 (en) | Methods for treating cognitive disorders using 3-aryl-3-hydroxy-2-amino-propionic acid amides, 3-heteroaryl-3-hydroxy-2-amino-propionic acid amides and related compounds |